FORMULATION AND EVALUATION OF FLOATING ORAL IN-SITU GELLING SYSTEM OF LOSARTAN POTASSIUM

Losartan potassium is used to treat hypertension, and it protects the kidneys from diabetic nephropathy. The drug has a short plasma half-life, inadequate bioavailability, removed rapidly from the blood circulation. These problems can be eliminated by formulating a novel dosage form of a drug in the form of floating oral in-situ gel. Present research performed on losartan potassium drug deals with the preparation and valuation of floating oral in-situ gel of the polymers used in-situ gel formation has many benefits like the sustained effect of drug substance and prolonged action in comparison to conventional drug delivery systems and good patient compliance, good stability and biocompatibility characteristics. The objective of this study was to develop an optimized in-situ oral gel of losartan potassium suitable to be administered by an oral route which upon exposure to physiological conditions changes to the gel phase. The aim of developing in-situ gel of losartan potassium was achieved through formulation designing of various formulations using various combinations of polymers and a cross-linking agent. Optimization of the prepared formulations for gelling capacity and floating behavior and evaluation of optimized formulations. All the optimized in-situ gel formulations exhibited the expected viscosity, pH, in-vitro gelling capacity, in-vitro floating ability, and sustained drug release.